Endocrine Abstracts

Objective: Some patients with Graves’ disease (GD) respond faster to antithyroid drugs (ATD) than others. Our aim was to study if levels of autoantibodies to the TSH-receptor (TRAb), thyroid-stimulating immunoglobulin (TSI), thyroid peroxidase antibodies (anti-TPO) and/or clinical factors influence the early response to anti thyroid drugs (ATD) in women with GD.Methods: This was a longitudinal cohort study of 65 women with GD and fT4 ≥50 pmol/...

Background: Mental fatigue, depression and anxiety are common in Graves’ disease (GD). Our aims were to assess the relationship between these variables among GD patients both in the hyperthyroid phase and after treatment. The pathogenic mechanisms involved in these symptoms are unknown and so is if previous psychiatric disease influences these symptoms.Methods: This was a longitudinal case control study in Göteborg, Sweden, on 65 women with new...

Background: Graves orbitopathy (GO) is the most frequent and feared complication of Graves’ disease. In moderate-severe cases, intravenous (iv) glucocorticoids (GC) is the first-line treatment while Rituximab (RTX) is recommended as second-line treatment in patients non-responsive to GC. But data is scarce and contradictory.Objective: To investigate if patients with GO and poor response to iv GC benefit from a switch to RTX early in the treatment co...

Introduction: Graves’ disease (GD) can negatively affect the quality of life. Research on GD in childhood, accounting for 1-5% of cases, has so far predominantly focused on treatment results. There is limited knowledge about association with other diseases and long-term psychosocial effects.Aims: We aimed to compare disease burden and psychosocial outcomes between childhood/young adult GD patients and unexposed population controls.<p class="abst...